Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
Enter any scientific lab and among the first tools
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micr
AstraZeneca in June chose Emergent to assist make 300 million doses of its possible COVID-19 vaccine vowed to the USA.
AstraZeneca has signed manufacturing deals internationally to meet its goal of earning 2 billion gallons of this vaccine, for example with just two Bill Gates-backed ventures and a $1.2 billion deal with the US authorities.
The company’s vaccine, which is co-developed from the University of Oxford, is among the very first to move into mid-stage trials. There are no approved vaccines or treatments for COVID-19, the highly infectious respiratory illness brought on by the novel coronavirus.
The latest contract follows a $87 million deal in June where Emergent signed an agreement to become the growth partner for AstraZeneca’s COVID-19 vaccine candidate.
Activities under the agreement will likely be at Emergent’s Baltimore Bayview centre, the company said, which is a designated centre by the US Department of Health and Human Services for rapid manufacturing of large quantities of vaccines and treatments.
